(BMRN) Biomarin Pharmaceutical - Ratings and Ratios
Enzyme replacement therapy for mucopolysaccharidosis, achondroplasia injection, phenylketonuria enzyme therapy, Batten disease enzyme therapy, hemophilia gene therapy
BMRN EPS (Earnings per Share)
BMRN Revenue
Description: BMRN Biomarin Pharmaceutical October 30, 2025
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a U.S.-based biotech that develops and commercializes therapies for rare, life-threatening diseases across North America, Europe, Latin America, the Middle East, and the Asia-Pacific. Its approved portfolio includes VIMIZIM (MPS IV A), VOXZOGO (achondroplasia), NAGLAZYME (MPS VI), PALYNZIQ (phenylketonuria), BRINEURA (Batten disease), ALDURAZYME (MPS I), KUVAN (PKU), and ROCTAVIAN (severe hemophilia A). The company also maintains a pipeline of next-generation products such as BMN 333 (long-acting CNP for growth disorders), BMN 349 (oral therapy for alpha-1 antitrypsin deficiency–related liver disease), and BMN 351 (oligonucleotide for Duchenne muscular dystrophy). Distribution is handled through specialty pharmacies, hospitals, government agencies, and wholesale partners, and BioMarin leverages collaborations with Catalyst Pharmaceutical Partners and Ares Trading.
Key recent metrics: 2023 total revenue reached $2.5 billion, with > 70 % derived from orphan-drug sales, reflecting the premium pricing power typical of rare-disease therapeutics. R&D intensity remains high at roughly 30 % of revenue, underscoring the company’s commitment to pipeline expansion. The broader biotechnology sector is benefiting from accelerated FDA “priority review” pathways and favorable reimbursement trends for gene-therapy and enzyme-replacement products, which can materially boost BioMarin’s launch success probability.
For a deeper, data-driven assessment of BioMarin’s valuation assumptions and scenario analysis, you may find the detailed analytics on ValueRay worth exploring.
BMRN Stock Overview
| Market Cap in USD | 9,973m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1999-07-23 |
BMRN Stock Ratings
| Growth Rating | -59.6% |
| Fundamental | 87.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -32.8% |
| Analyst Rating | 4.34 of 5 |
BMRN Dividends
Currently no dividends paidBMRN Growth Ratios
| Growth Correlation 3m | -82.6% |
| Growth Correlation 12m | -82.9% |
| Growth Correlation 5y | -32.7% |
| CAGR 5y | -13.38% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.24 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.43 |
| Sharpe Ratio 12m | 0.24 |
| Alpha | -30.17 |
| Beta | 0.330 |
| Volatility | 29.68% |
| Current Volume | 2120.5k |
| Average Volume 20d | 2343.5k |
| Stop Loss | 50.9 (-3.6%) |
| Signal | 0.07 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (520.4m TTM) > 0 and > 6% of Revenue (6% = 185.6m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 6.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 98.78% (prev 85.04%; Δ 13.74pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 914.0m > Net Income 520.4m (YES >=105%, WARN >=100%) |
| Net Debt (-653.4m) to EBITDA (772.4m) ratio: -0.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (192.0m) change vs 12m ago -2.59% (target <= -2.0% for YES) |
| Gross Margin 81.32% (prev 78.95%; Δ 2.38pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.78% (prev 40.18%; Δ 2.60pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 64.46 (EBITDA TTM 772.4m / Interest Expense TTM 10.7m) >= 6 (WARN >= 3) |
Altman Z'' 3.46
| (A) 0.40 = (Total Current Assets 3.85b - Total Current Liabilities 798.4m) / Total Assets 7.61b |
| (B) 0.03 = Retained Earnings (Balance) 200.8m / Total Assets 7.61b |
| (C) 0.10 = EBIT TTM 689.6m / Avg Total Assets 7.23b |
| (D) 0.10 = Book Value of Equity 155.7m / Total Liabilities 1.56b |
| Total Rating: 3.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.56
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 9.14% = 4.57 |
| 3. FCF Margin 26.87% = 6.72 |
| 4. Debt/Equity 0.10 = 2.50 |
| 5. Debt/Ebitda -0.85 = 2.50 |
| 6. ROIC - WACC (= 5.69)% = 7.11 |
| 7. RoE 8.84% = 0.74 |
| 8. Rev. Trend 96.21% = 7.22 |
| 9. EPS Trend 64.19% = 3.21 |
What is the price of BMRN shares?
Over the past week, the price has changed by +1.81%, over one month by -5.05%, over three months by -14.74% and over the past year by -20.05%.
Is Biomarin Pharmaceutical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BMRN is around 44.51 USD . This means that BMRN is currently overvalued and has a potential downside of -15.7%.
Is BMRN a buy, sell or hold?
- Strong Buy: 16
- Buy: 7
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BMRN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.9 | 72.1% |
| Analysts Target Price | 90.9 | 72.1% |
| ValueRay Target Price | 48.9 | -7.4% |
BMRN Fundamental Data Overview November 01, 2025
P/E Trailing = 19.2974
P/E Forward = 10.8342
P/S = 3.2232
P/B = 1.7704
P/EG = 0.6335
Beta = 0.33
Revenue TTM = 3.09b USD
EBIT TTM = 689.6m USD
EBITDA TTM = 772.4m USD
Long Term Debt = 595.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 7.57m USD (from shortTermDebt, last fiscal year)
Debt = 596.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -653.4m USD (from netDebt column, last quarter)
Enterprise Value = 9.09b USD (9.97b + Debt 596.7m - CCE 1.48b)
Interest Coverage Ratio = 64.46 (Ebit TTM 689.6m / Interest Expense TTM 10.7m)
FCF Yield = 9.14% (FCF TTM 831.4m / Enterprise Value 9.09b)
FCF Margin = 26.87% (FCF TTM 831.4m / Revenue TTM 3.09b)
Net Margin = 16.82% (Net Income TTM 520.4m / Revenue TTM 3.09b)
Gross Margin = 81.32% ((Revenue TTM 3.09b - Cost of Revenue TTM 577.9m) / Revenue TTM)
Gross Margin QoQ = 81.95% (prev 81.82%)
Tobins Q-Ratio = 1.19 (Enterprise Value 9.09b / Total Assets 7.61b)
Interest Expense / Debt = 0.43% (Interest Expense 2.58m / Debt 596.7m)
Taxrate = -16.79% (negative due to tax credits) (4.42m / -26.3m)
NOPAT = 805.4m (EBIT 689.6m * (1 - -16.79%)) [negative tax rate / tax credits]
Current Ratio = 4.83 (Total Current Assets 3.85b / Total Current Liabilities 798.4m)
Debt / Equity = 0.10 (Debt 596.7m / totalStockholderEquity, last quarter 6.06b)
Debt / EBITDA = -0.85 (Net Debt -653.4m / EBITDA 772.4m)
Debt / FCF = -0.79 (Net Debt -653.4m / FCF TTM 831.4m)
Total Stockholder Equity = 5.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.83% (Net Income 520.4m / Total Assets 7.61b)
RoE = 8.84% (Net Income TTM 520.4m / Total Stockholder Equity 5.88b)
RoCE = 10.64% (EBIT 689.6m / Capital Employed (Equity 5.88b + L.T.Debt 595.1m))
RoIC = 12.54% (NOPAT 805.4m / Invested Capital 6.42b)
WACC = 6.85% (E(9.97b)/V(10.57b) * Re(7.23%) + D(596.7m)/V(10.57b) * Rd(0.43%) * (1-Tc(-0.17)))
Discount Rate = 7.23% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈619.2m ; Y1≈763.8m ; Y5≈1.30b
Fair Price DCF = 115.4 (DCF Value 22.17b / Shares Outstanding 192.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 64.19 | EPS CAGR: 69.02% | SUE: -2.97 | # QB: 0
Revenue Correlation: 96.21 | Revenue CAGR: 14.29% | SUE: -0.13 | # QB: 0
Additional Sources for BMRN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle